Xiaorui Fu

2.1k total citations
91 papers, 1.2k citations indexed

About

Xiaorui Fu is a scholar working on Pathology and Forensic Medicine, Oncology and Immunology. According to data from OpenAlex, Xiaorui Fu has authored 91 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Pathology and Forensic Medicine, 39 papers in Oncology and 28 papers in Immunology. Recurrent topics in Xiaorui Fu's work include Lymphoma Diagnosis and Treatment (49 papers), Immune Cell Function and Interaction (18 papers) and Viral-associated cancers and disorders (16 papers). Xiaorui Fu is often cited by papers focused on Lymphoma Diagnosis and Treatment (49 papers), Immune Cell Function and Interaction (18 papers) and Viral-associated cancers and disorders (16 papers). Xiaorui Fu collaborates with scholars based in China, United States and Pakistan. Xiaorui Fu's co-authors include Yu Chang, Zhaoming Li, Zhenchang Sun, Jingjing Wu, Lei Zhang, Xinhua Wang, Ling Li, Mingzhi Zhang, Mingzhi Zhang and Feifei Nan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Xiaorui Fu

87 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiaorui Fu China 19 639 605 374 360 224 91 1.2k
Hyeon Seok Eom South Korea 15 671 1.1× 590 1.0× 239 0.6× 392 1.1× 136 0.6× 58 1.3k
Huiqiang Huang China 16 321 0.5× 352 0.6× 158 0.4× 218 0.6× 93 0.4× 79 819
Zhenchang Sun China 15 452 0.7× 384 0.6× 267 0.7× 148 0.4× 71 0.3× 38 709
Sheeja T. Pullarkat United States 13 272 0.4× 508 0.8× 179 0.5× 234 0.7× 61 0.3× 43 980
Paul Drillenburg Netherlands 20 350 0.5× 442 0.7× 313 0.8× 374 1.0× 196 0.9× 37 1.4k
Sheng Yang China 16 289 0.5× 406 0.7× 192 0.5× 149 0.4× 83 0.4× 105 781
Josef Birkmann Germany 22 373 0.6× 569 0.9× 454 1.2× 150 0.4× 52 0.2× 53 1.3k
Luca Paoluzzi United States 16 218 0.3× 478 0.8× 134 0.4× 505 1.4× 73 0.3× 41 1.0k
Lai‐Fa Sheu Taiwan 21 226 0.4× 330 0.5× 136 0.4× 439 1.2× 150 0.7× 44 1.1k

Countries citing papers authored by Xiaorui Fu

Since Specialization
Citations

This map shows the geographic impact of Xiaorui Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaorui Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaorui Fu more than expected).

Fields of papers citing papers by Xiaorui Fu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaorui Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaorui Fu. The network helps show where Xiaorui Fu may publish in the future.

Co-authorship network of co-authors of Xiaorui Fu

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaorui Fu. A scholar is included among the top collaborators of Xiaorui Fu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaorui Fu. Xiaorui Fu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fu, Xiaorui, Yan Zhang, Fang Liu, et al.. (2025). Ketogenic diet treatment for super-refractory status epilepticus in the intensive care unit: feasibility, safety and effectiveness. Frontiers in Neurology. 15. 1517850–1517850. 2 indexed citations
2.
Chen, Yubao, Jun Huang, Wei Zhang, et al.. (2025). Designing ecological buffer zones for sustainable agriculture: A case study of Fuxian Lake. Results in Engineering. 26. 105333–105333. 2 indexed citations
3.
Zhang, Mengjie, Yi‐Rong Chen, Caixia Zhang, et al.. (2025). Development of a 177Lu-labeled EphA2-targeting cyclic peptide combined with an HPK1 inhibitor for synergistic anti-tumor effects. Cellular Oncology. 48(6). 1757–1774.
4.
Luo, Jing‐chao, Sen Lu, Xiaorui Fu, et al.. (2024). Comparison of Oliceridine to Remifentanil for Optimal Analgesia in Mechanical Ventilation (CO-ROAM): Study Protocol for a Multicenter Randomized Controlled Trial. Pain and Therapy. 13(6). 1695–1704. 4 indexed citations
5.
6.
Liu, Quanlin, et al.. (2023). N-carbamylglutamate, a promising functional feed additive in swine production: A review. Animal Feed Science and Technology. 303. 115719–115719. 1 indexed citations
7.
Zhang, Xudong, Xiaoyan Feng, Meng Dong, et al.. (2023). Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma. Cancer Medicine. 12(7). 8134–8143. 7 indexed citations
8.
Zhou, Zhi‐Yuan, Lei Zhang, Xinhua Wang, et al.. (2021). Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma. Annals of Hematology. 100(6). 1509–1516. 10 indexed citations
9.
Li, Ling, Lei Zhang, Xin Li, et al.. (2021). Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study. Indian Journal of Hematology and Blood Transfusion. 38(1). 42–50. 2 indexed citations
10.
Yu, Hui, Xiaorui Fu, Lei Zhang, et al.. (2021). Clinical analysis of patients with primary and secondary extranodal natural killer/T‐cell lymphoma of central nervous system. Hematological Oncology. 41(2). 267–274. 2 indexed citations
11.
Li, Xin, Xinhua Wang, Lei Zhang, et al.. (2021). Characteristics and Clinical Implications of the Nasal Microbiota in Extranodal NK/T-Cell Lymphoma, Nasal Type. Frontiers in Cellular and Infection Microbiology. 11. 686595–686595. 3 indexed citations
12.
13.
Zhang, Lei, Ling Li, Xin Li, et al.. (2020). <p>Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases</p>. OncoTargets and Therapy. Volume 13. 7189–7197. 11 indexed citations
14.
Lv, Yunxia, Jinzhong Duanmu, Xiaorui Fu, Taiyuan Li, & Qunguang Jiang. (2020). Identifying a new microRNA signature as a prognostic biomarker in colon cancer. PLoS ONE. 15(2). e0228575–e0228575. 23 indexed citations
15.
Li, Ling, Fei Kong, Lei Zhang, et al.. (2020). Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study. Investigational New Drugs. 38(6). 1847–1853. 28 indexed citations
16.
Zhang, Xudong, Xiaorui Fu, Zhaoming Li, et al.. (2019). c‐Myc mediated upregulation of long noncoding RNA SNHG12 regulates proliferation and drug sensitivity in natural killer/T‐cell lymphoma. Journal of Cellular Biochemistry. 120(8). 12628–12637. 38 indexed citations
17.
18.
Li, Ling, Ken H. Young, Lei Zhang, et al.. (2017). Efficacy and Safety of Novel Targeted Drug' Apatinib in Relapse or Refractory Non-Hodgkin Lymphoma: An Open Label, Single-Armed, Exploratory Study. Blood. 130. 1548–1548. 2 indexed citations
19.
Cui, Yingying, Xin Li, Zhenchang Sun, et al.. (2015). Safety and efficacy of low-dose pre-phase before conventional-dose chemotherapy for ulcerative gastric diffuse large B-cell lymphoma. Leukemia & lymphoma. 56(9). 2613–2618. 11 indexed citations
20.
Sun, Zhenchang, Xin Li, Xiaolong Wu, et al.. (2014). Clinical analysis of chronic lung injury in patients with non-Hodgkin lymphoma after CHOP chemotherapy. Tumor Biology. 35(12). 12601–12605.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hyeon Seok Eom Breakdown of academic impact, for papers by Huiqiang Huang Breakdown of academic impact, for papers by Zhenchang Sun Breakdown of academic impact, for papers by Sheeja T. Pullarkat Breakdown of academic impact, for papers by Paul Drillenburg Breakdown of academic impact, for papers by Sheng Yang Breakdown of academic impact, for papers by Josef Birkmann Breakdown of academic impact, for papers by Luca Paoluzzi Breakdown of academic impact, for papers by Lai‐Fa Sheu
Rankless by CCL
2026